28 Jun 2021 --- NovoBiome is building a “disruptive” ex-vivo research and discovery platform called NovoSift to analyze the symbiotic relationship between the microbiota and the human intestine. The new platform will “rationally identify” live biotherapeutic products (LBPs) based on a better understanding of functions and mechanisms.
